A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma

Starting soon · Phase 1

Conditions studied: Multiple Myeloma in Relapse, Multiple Myeloma (MM)

In brief

This study is a Phase 1 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV500. The study will enroll patients with relapsed/refractory multiple myeloma.

Key facts

Study ID

NCT07735546

Run by

Umoja Biopharma

People needed

100

Starts

2026-10-01

Expected to finish

2029-12-31

Last updated by the study team

2026-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older
• Provides voluntary written informed consent
• Relapsed or refractory multiple myeloma (MM) following treatment with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody
• Measurable disease following completion of most recent anticancer therapy
• No serious concomitant diseases or active/uncontrolled infections
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate organ function

You may not qualify if…

• Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or primary AL amyloidosis
• Solitary plasmacytomas without evidence of systemic disease
• Women who are pregnant or breastfeeding
• Current isolated central nervous system (CNS) involvement
• Prior allogeneic bone marrow transplant, gene therapy, or adoptive cell transfer (except tumor-infiltrating lymphocytes, CAR-NK cells, T-cell receptor [TCR] fusion constructs, TCR T cells, and CAR T cells)
• History of or active human immunodeficiency virus (HIV)
• Active or chronic hepatitis B, or active hepatitis C
• Systemic immunodeficiency diseases, except for well-controlled Type I diabetes or thyroid disease
• Ongoing CNS disease that would preclude neurologic assessment
• Uncontrolled angina or other acute heart disease
• Currently receiving treatment in another interventional clinical trial.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.